نتایج جستجو برای: pik3ca

تعداد نتایج: 2433  

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2007
Naomi Maruyama Yasuo Miyoshi Tetsuya Taguchi Yasuhiro Tamaki Morito Monden Shinzaburo Noguchi

PURPOSE Somatic mutations of PIK3CA, which encodes the p110alpha catalytic subunit of phosphatidylinositol 3-kinase, have recently been shown to play an important role in the pathogenesis and progression of human breast cancers. In this study, the frequency of PIK3CA mutations and their relationship with clinicopathologic and biological variables were investigated in Japanese breast cancers. ...

2015
YOSHIHITO IIJIMA MASAHIRO SEIKE RINTARO NORO TAKAYUKI IBI SHINGO TAKEUCHI IWAO MIKAMI KIYOSHI KOIZUMI JITSUO USUDA AKIHIKO GEMMA

The recent development of human genome studies has demonstrated the possibility of alteration of several genes as oncogenic driver mutations of lung squamous cell carcinoma (SQCC). FGFR1, PIK3CA and SOX2 genes have been recognized as candidate driver genes of SQCC. The aim of the present study was to evaluate FGFR1, PIK3CA and SOX2 protein expression in SQCC and determine whether the expression...

Journal: :Molecular cancer therapeutics 2011
Filip Janku Apostolia M Tsimberidou Ignacio Garrido-Laguna Xuemei Wang Rajyalakshmi Luthra David S Hong Aung Naing Gerald S Falchook John W Moroney Sarina A Piha-Paul Jennifer J Wheler Stacy L Moulder Siqing Fu Razelle Kurzrock

Preclinical data suggest that PIK3CA mutations predict response to PI3K/AKT/mTOR inhibitors. Concomitant KRAS or BRAF mutations may mediate resistance. Therefore, tumors from patients referred to the phase I program for targeted therapy starting in October 2008 were analyzed for PIK3CA mutations using PCR-based DNA sequencing of exons 9 and 20. Consecutive patients with diverse tumor types and ...

2017
Wenli Cui Mingfu Ma Shutao Zheng Zhiping Ma Liping Su Wei Zhang

Although it has been known that PIK3CA was amplified and PTEN was deficient on protein level in DLBCL, the clinicopathological significance of PIK3CA and PTEN genetic change on DNA level hasn't been established. Here, in our present study, to understand the clinical significance of genetic status of PIK3CA and PTEN in DLBCL, fluorescent in-situ hybridization (FISH) was employed to evaluate the ...

2013
Christophe Rosty Joanne P. Young Michael D. Walsh Mark Clendenning Kristy Sanderson Rhiannon J. Walters Susan Parry Mark A. Jenkins Aung Ko Win Melissa C. Southey John L. Hopper Graham G. Giles Elizabeth J. Williamson Dallas R. English Daniel D. Buchanan

Mutations in PIK3CA are present in 10 to 15% of colorectal carcinomas. We aimed to examine how PIK3CA mutations relate to other molecular alterations in colorectal carcinoma, to pathologic phenotype and survival. PIK3CA mutation testing was carried out using direct sequencing on 757 incident tumors from the Melbourne Collaborative Cohort Study. The status of O-6-methylguanine-DNA methyltransfer...

2016
Shang-Gin Wu Yih-Leong Chang Chong-Jen Yu Pan-Chyr Yang Jin-Yuan Shih

To understand the impact of PIK3CA mutations on clinical characteristics and treatment response to epidermal growth factor tyrosine kinase inhibitors (EGFR TKIs) of lung adenocarcinoma, we examined PIK3CA and EGFR mutations in lung adenocarcinoma patients, and analyzed their clinical outcomes. Surgically excised tumor, bronchoscopy biopsy/brushing specimens and pleural effusions were prospectiv...

Journal: :Endocrine-related cancer 2009
Yong Lin Xiaofei Jiang Ye Shen Min Li Huili Ma Mingzhao Xing Yuan Lu

Genetic alterations in the PIK3CA gene of the phosphoinositide 3-kinase (PI3K)/AKT pathway have been found in many human tumors, but they have not been explored in pituitary tumors. We undertook the present study to explore mutations and amplifications of the PIK3CA gene in pituitary tumors. DNA sequencing and real-time quantitative PCR were used to examine mutations and amplifications respecti...

2015
James E. Korkola Eric A. Collisson Laura M. Heiser Chris Oates Nora Bayani Sleiman Itani Amanda Esch Wallace Thompson Obi L. Griffith Nicholas J. Wang Wen-Lin Kuo Brian Cooper Jessica Billig Safiyyah Ziyad Jenny L. Hung Lakshmi Jakkula Heidi Feiler Yiling Lu Gordon B. Mills Paul T. Spellman Claire Tomlin Sach Mukherjee Joe W. Gray

We report here on experimental and theoretical efforts to determine how best to combine drugs that inhibit HER2 and AKT in HER2(+) breast cancers. We accomplished this by measuring cellular and molecular responses to lapatinib and the AKT inhibitors (AKTi) GSK690693 and GSK2141795 in a panel of 22 HER2(+) breast cancer cell lines carrying wild type or mutant PIK3CA. We observed that combination...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2006
Monica Prasad Hayes Hong Wang Rosanny Espinal-Witter Wayne Douglas Garron J Solomon Suzanne J Baker Lora Hedrick Ellenson

PURPOSE The tumor suppressor PTEN gene and the PIK3CA oncogene are frequently mutated in uterine endometrioid carcinoma (UEC). PTEN mutations are also common in complex atypical hyperplasia (CAH), the precursor lesion of UEC. The status of PIK3CA has not yet been explored in CAH. In this study, we evaluated both CAH and UEC for PTEN and PIK3CA mutations. EXPERIMENTAL DESIGN Neoplastic tissue ...

2015
Toru Mukohara

The PI3K pathway is the most frequently enhanced oncogenic pathway in breast cancer. Among mechanisms of PI3K enhancement, PIK3CA mutations are most frequently (∼30%) observed, along with protein loss of PTEN. Since the first discovery of PIK3CA mutations in solid malignancies in 2004, numerous studies have revealed the prognostic and therapeutic implications of these mutations. Although many i...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید